A prospective evaluation of COVID-19 associated coagulopathy with acute coronary syndrome (ACS)
| العنوان: | A prospective evaluation of COVID-19 associated coagulopathy with acute coronary syndrome (ACS) |
|---|---|
| المؤلفون: | I Pescetelli, M Marchetti, P Gomez Rosas, E Sanga, L Russo, F Moretti, D Pellegrini, L Fiocca, P A Canova, A Vassileva, S Gamba, C Verzeroli, A Grosu, G Guagliumi, A Falanga |
| المصدر: | European Heart Journal. 42 |
| بيانات النشر: | Oxford University Press (OUP), 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Cardiology and Cardiovascular Medicine |
| الوصف: | Background Hospitalised COVID-19 pneumonia patients are characterised by the occurrence of a hypercoagulable state associated to a high risk of thromboembolic events. The main laboratory findings of this coagulopathy include D-dimer increase, mild thrombocytopenia, prolonged PT, and increase endothelial activation biomarkers (vWF, thrombomodulin). No data are available about coagulation profile in patients presenting with an acute coronary syndrome (ACS) combined with SARS-CoV-2 infection. Purpose In this prospective study, we aimed to evaluate the contribute of concomitant SARS-CoV-2 infection to the haemostatic system derangement (i.e., from endothelial cell activation to fibrinolytic phase) observed in patients presenting with ACS. Further, the role of haemostatic biomarkers (HB) for in-hospital mortality risk prediction was also explored. Methods Consecutive patients admitted to our hospital for ACS at peak intensity of local pandemia were enrolled into this study. At admission, all patients underwent routine blood examinations with blood count, serum biochemical tests and an extensive coagulation profiling. Data from coronary angiography and percutaneous coronary intervention (PCI), when performed, were collected. In-hospital major adverse cardio and cerebrovascular events –MACCEs- (total and cardiovascular death, stroke, systemic or pulmonary embolism, re-MI and bleedings) are reported. Results A total of 99 (76M/23F) consecutive patients with a median age of 66.7 (±12.1) were enrolled. According to nasal swab, 24 patients were SARS-CoV-2 positive and 75 negative. The two groups, similar in age, sex and cardiovascular risk factors, significantly differed in presenting symptoms (p Conclusions In patients presenting with ACS combined with SARS-Cov-2 infection an additional HB asset derangement with stronger endothelial cell activation occurs which negatively impact the outcome, regardless of the invasive treatment. Funding Acknowledgement Type of funding sources: None. |
| تدمد: | 1522-9645 0195-668X |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::939913029151c227d99061f051b0a94b https://doi.org/10.1093/eurheartj/ehab724.1288 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi...........939913029151c227d99061f051b0a94b |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15229645 0195668X |
|---|